– credit NIH
In experiments involving mice, scientists successfully eliminated an aggressive childhood brain cancer while also providing lasting protection.
The scientists, from UC San Francisco, utilized a new type of immune cell therapy that activates only after entering the brain, allowing it to attack cancer while remaining inactive elsewhere in the body.
When researchers introduced cancer cells again several weeks later, the immune cells continued fighting and prevented new tumors from developing.
The promising results were spoken of like a “cure,” and have prompted scientists to rapidly prepare for clinical trials in humans at UCSF Health, potentially beginning as early as April 2027.
The target of the experiments was diffuse midline glioma (DMG) described by one scientist involved in the project as a “heartbreaking” diagnosis.
Although the treatment has not yet been tested for effectiveness in humans, its ability to completely eliminate tumors and prevent their return in mice has generated considerable optimism.
“Diffuse midline glioma is a heartbreaking diagnosis for patients and their families,” said Sabine Mueller, MD, PhD, and Director of the UCSF Pediatric Brain Tumor Center. “This preclinical data is very promising. Mice with DMG are being cured, and we are incredibly excited to bring this therapy to the children and young adults we care for. This is exactly the kind of innovative approach they deserve.”
DMG is among the most difficult childhood cancers to treat. It grows into the brainstem, a critical region that regulates breathing, heartbeat, and swallowing. Nearly all children diagnosed with the disease die within a year, and existing treatments have had little success in stopping its progression.
The experimental therapy, called B-SYNC CAR-T, could offer a new way forward. Unlike conventional CAR-T treatments, which have struggled against brain tumors, these modified immune cells are programmed to activate their cancer-fighting machinery specifically within the brain.
“It’s been a struggle to make CAR-T cells that overcome DMG without causing unacceptable side effects,” said Hideho Okada, professor of Neurological Surgery at UCSF and co-corresponding author of the mouse experiment, published in Science Translational Medicine.
“By limiting B-SYNC’s CAR expression to when and where it matters—in the brain—we saw consistent, total shutdown of DMG tumors in the lab.”
CAR-T therapy works by modifying the body’s T cells, a type of immune cell, so they carry special receptors called CARs. These receptors recognize proteins on cancer cells and trigger an immune attack, thus bypassing cancer’s natural cloaking mechanism.
Although CAR-T treatments have shown success against certain cancers, brain tumors have remained particularly difficult to overcome. Building on previous work with CAR-T therapy by Professor Okada, the team behind this mouse model identified that brevican—a protein naturally distributed throughout the brain—could be a promising signal for triggering the CAR-T immune response.
The scientists redesigned a previously tested molecular sensing system called synNotch so that it would trigger CAR production only when it encountered brevican. Once activated, these B-SYNC CAR-T cells could search for cancer cells carrying 2 tumor-associated proteins called EphA2 and IL13Rα2.
This meant the engineered immune cells no longer depended on a tumor-specific mutation to become active. Instead, they used a protein associated with the brain itself as the signal to begin their attack.
Although B-SYNC was initially developed for glioblastoma, another kind of brain cancer, the researchers recognized that it might also work against DMG. Both cancers commonly display EphA2 and IL13Rα2 on their tumor cells, making them potential targets for the same treatment.
Senthilnath Lakshmanachetty, PhD, a postdoctoral researcher in Okada’s laboratory, led experiments to investigate whether B-SYNC could successfully attack this deadly childhood cancer.
The researchers first administered B-SYNC CAR-T cells in the bloodstream to mice implanted with human DMG cells. Arriving in the brain, they began producing the cancer-targeting CAR receptors and attacking tumor cells.
BRAIN CANCER SURVIVORS: Artist Beats Brain Cancer And Paints Amazing Portraits of Hospital Staff as Thank-you Gifts (LOOK)
Importantly, this activation appeared to occur only in the intended location. B-SYNC cells elsewhere in the body, including those circulating in the blood or present in the spleen, did not produce the CAR receptors.
That was “just as we designed it,” Lakshmanachetty said.
The team next examined whether delivering the treatment directly into the brain would produce stronger effects. The results were striking. In two mouse models containing human DMG tumors, the treatment completely eliminated the cancer in every mouse tested. Conventional CAR-T cells, by comparison, were unable to bring the tumors under control.
Destroying the original tumors was only part of the achievement. The researchers also wanted to determine whether the engineered immune cells could remain active and protect against cancer returning.
BEATING CANCER: Antiviral Chewing Gum Cuts Risk of Certain Head and Neck Cancers to Almost Zero in New Study
Nearly 7 weeks after the initial treatment, they introduced another round of DMG cells into mice that had already received B-SYNC. Every treated mouse rejected the new cancer cells, demonstrating that the therapy’s protective effects continued well beyond the initial elimination of the tumors.
Further observations showed that B-SYNC cells remained functional more than 70 days after treatment.
With the laboratory results demonstrating both tumor elimination and lasting immune activity, the UCSF team is now working to move B-SYNC into human testing.
CAR-T MAGIC: CAR-T Cell Therapy Achieves Near-Complete Tumor Regression in Brain Cancer After Five Days
Okada, Lakshmanachetty, and their colleagues are collaborating with UCSF cancer specialists to prepare clinical trials. The proposed treatment will use each patient’s own T cells, which will be genetically modified to become B-SYNC CAR-T cells.
The transition from laboratory research to clinical testing is moving relatively quickly, reflecting the encouraging findings from the animal experiments.
The first trial will be co-led by Dr. Mueller, while researchers plan to evaluate different combinations of intravenous delivery and direct administration into the brain.
CELEBRATE The News Of This Unprecedented, Early Stage Cancer Success On Social Media…

